上海交通大学学报（医学版）

上海交通大学学报（医学版） >

2022 , Vol. 42 >Issue 3: 364 - 368

DOI: https://doi.org/10.3969/j.issn.1674-8115.2022.03.015

综述

肠道微生物组在炎症性肠病发病机制和治疗中的作用研究进展

  • 李博文 ,
  • 刘宁宁 ,
  • 王慧
展开
  • 上海交通大学公共卫生学院，上海 200025
李博文（1996—），女，硕士生；电子信箱：maylee59@foxmail.com。
王 慧，电子信箱：huiwang@shsmu.edu.cn。
刘宁宁，电子信箱：liuningning@shsmu.edu.cn

收稿日期: 2021-11-04

  网络出版日期: 2022-05-09

基金资助

国家重点研发计划(2020YFA0907200);国家自然科学基金(81630086)

收起

Advances in gut microbiota in the pathogenesis and treatment of inflammatory bowel disease

  • Bowen LI ,
  • Ningning LIU ,
  • Hui WANG
Expand
  • Shanghai Jiao Tong University School of Public Health, Shanghai 200025, China
WANG Hui, E-mail: huiwang@shsmu.edu.cn.
LIU Ningning, E-mail: liuningning@shsmu.edu.cn

Received date: 2021-11-04

  Online published: 2022-05-09

Supported by

National Key R&D Program of China(2020YFA0907200);National Natural Science Foundation of China(81630086)

Fold

摘要

肠道微生物组在人体健康中起着至关重要的作用。炎症性肠病（inflammatory bowel disease，IBD）是一种由多种环境因素（包括肠道微生物组）在遗传易感个体中引起的免疫疾病。尽管大多数研究表明肠道微生物组及其代谢物通过诱导炎症和免疫紊乱在肠道疾病的发生和发展中发挥作用，但仍无法确定微生物组与IBD发病机制之间的因果关系。该文总结了IBD发病过程中细菌、真菌和病毒微生物组的改变以及潜在的功能途径，探讨当前针对微生物组的治疗方法和前景。

关键词： 炎症性肠病; 生态失调; 微生物组; 真菌

本文引用格式

李博文 , 刘宁宁 , 王慧 . 肠道微生物组在炎症性肠病发病机制和治疗中的作用研究进展[J]. 上海交通大学学报（医学版）, 2022 , 42(3) : 364 -368 . DOI: 10.3969/j.issn.1674-8115.2022.03.015

Abstract

The gut microbiota plays a critical role in human health. Inflammatory bowel disease (IBD) is an immunological disease caused by various environmental factors, including the gut microbiota, in genetically susceptible individuals. Although most studies have indicated the role of gut microbiota and their metabolites in contribution to the occurrence and development of intestinal diseases by inducing inflammation and immune disorders. However, the causal relationship between microbiota and IBD pathogenesis cannot be determined. In this review, the alteration of bacterial, fungal and viral microbiota and the potential functional pathways during IBD pathogenesis are summarized. Besides, the current therapeutic approaches targeting microbiota and the promising perspectives are introduced.

Key words： inflammatory bowel disease (IBD); dysbiosis; microbiota; fungus

参考文献

1 GILBERT J A, BLASER M J, CAPORASO J G, et al. Current understanding of the human microbiome[J]. Nat Med, 2018, 24(4): 392-400.
2 NG S C, KAPLAN G G, TANG W, et al. Population density and risk of inflammatory bowel disease: a prospective population-based study in 13 countries or regions in Asia-Pacific[J]. Am J Gastroenterol, 2019, 114(1): 107-115.
3 GUAN Q. A comprehensive review and update on the pathogenesis of inflammatory bowel disease[J]. J Immunol Res, 2019, 2019: 7247238.
4 PARK J, CHEON J H. Incidence and prevalence of inflammatory bowel disease across Asia[J]. Yonsei Med J, 2021, 62(2): 99-108.
5 LLOYD-PRICE J, ARZE C, ANANTHAKRISHNAN A N, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases[J]. Nature, 2019, 569(7758): 655-662.
6 HUGHES E R, WINTER M G, DUERKOP B A, et al. Microbial respiration and formate oxidation as metabolic signatures of inflammation-associated dysbiosis[J]. Cell Host Microbe, 2017, 21(2): 208-219.
7 KEITA ?V, ALKAISSI L Y, HOLM E B, et al. Enhanced E. coli LF82 translocation through the follicle-associated epithelium in Crohn's disease is dependent on long polar fimbriae and CEACAM6 expression, and increases paracellular permeability[J]. J Crohns Colitis, 2019, 14(2): 216-229.
8 PALMELA C, CHEVARIN C, XU Z, et al. Adherent-invasive Escherichia coli in inflammatory bowel disease[J]. Gut, 2018, 67(3): 574-587.
9 ALAM M T, AMOS G C A, MURPHY A R J, et al. Microbial imbalance in inflammatory bowel disease patients at different taxonomic levels[J]. Gut Pathog, 2020, 12: 1.
10 ISOBE J, MAEDA S, OBATA Y, et al. Commensal-bacteria-derived butyrate promotes the T-cell-independent IgA response in the colon[J]. Int Immunol, 2019, 32(4): 243-258.
11 GLASSNER K L, ABRAHAM B P, QUIGLEY E M M. The microbiome and inflammatory bowel disease[J]. J Allergy Clin Immunol, 2020, 145(1): 16-27.
12 LEYLABADLO H E, GHOTASLOU R, FEIZABADI M M, et al. The critical role of Faecalibacterium prausnitzii in human health: an overview[J]. Microb Pathog, 2020, 149: 104344.
13 ZHOU Y, XU H, XU J, et al. F. prausnitzii and its supernatant increase SCFAs-producing bacteria to restore gut dysbiosis in TNBS-induced colitis[J]. AMB Express, 2021, 11(1): 33.
14 QUéVRAIN E, MAUBERT MA, MICHON C, et al. Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease[J]. Gut, 2016, 65(3): 415-425.
15 ELSON C O, CONG Y. Host-microbiota interactions in inflammatory bowel disease[J]. Gut Microbes, 2012, 3(4): 332-344.
16 VICH VILA A, IMHANN F, COLLIJ V, et al. Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome[J]. Sci Transl Med, 2018, 10(472): eaap8914.
17 LUO W, SHEN Z, DENG M, et al. Roseburia intestinalis supernatant ameliorates colitis induced in mice by regulating the immune response[J]. Mol Med Rep, 2019, 20(2): 1007-1016.
18 HENKE M T, KENNY D J, CASSILLY C D, et al. Ruminococcus gnavus, a member of the human gut microbiome associated with Crohn's disease, produces an inflammatory polysaccharide[J]. PNAS, 2019, 116(26): 12672-12677.
19 DAI Z, ZHANG J, WU Q, et al. The role of microbiota in the development of colorectal cancer[J]. Int J Cancer, 2019, 145(8): 2032-2041.
20 BLANDFORD L E, JOHNSTON E L, SANDERSON J D, et al. Promoter orientation of the immunomodulatory Bacteroides fragilis capsular polysaccharide A (PSA) is off in individuals with inflammatory bowel disease (IBD)[J]. Gut Microbes, 2019, 10(5): 569-577.
21 LOPEZ-SILES M, ENRICH-CAPó N, ALDEGUER X, et al. Alterations in the abundance and co-occurrence of Akkermansia muciniphila and Faecalibacterium prausnitzii in the colonic mucosa of inflammatory bowel disease subjects[J]. Front Cell Infect Microbiol, 2018, 8: 281.
22 ZHANG T, JI X, LU G, et al. The potential of Akkermansia muciniphila in inflammatory bowel disease[J]. Appl Microbiol Biotechnol, 2021, 105(14/15): 5785-5794.
23 SOKOL H, LEDUCQ V, ASCHARD H, et al. Fungal microbiota dysbiosis in IBD[J]. Gut, 2017, 66(6): 1039-1048.
24 LIMON J J, SKALSKI J H, UNDERHILL D M. Commensal fungi in health and disease[J]. Cell Host Microbe, 2017, 22(2): 156-165.
25 Bojang E, Ghuman H, Kumwenda P, et al. Immune sensing of Candida albicans[J]. J Fungi (Basel), 2021, 7(2): 1-16.
26 HOARAU G, MUKHERJEE PK, GOWER-ROUSSEAU C, et al. Bacteriome and mycobiome interactions underscore microbial dysbiosis in familial Crohn's disease[J]. mBio, 2016, 7(5): e01250-16.
27 TANG C, KAMIYA T, LIU Y, et al. Inhibition of dectin-1 signaling ameliorates colitis by inducing Lactobacillus-mediated regulatory T cell expansion in the intestine[J]. Cell Host Microbe, 2015, 18(2): 183-197.
28 LIGUORI G, LAMAS B, RICHARD M L, et al. Fungal dysbiosis in mucosa-associated microbiota of Crohn's disease patients[J]. J Crohns Colitis, 2015, 10(3): 296-305.
29 SIVIGNON A, DE VALLéE A, BARNICH N, et al. Saccharomyces cerevisiae CNCM I-3856 prevents colitis induced by AIEC bacteria in the transgenic mouse model mimicking Crohn's disease[J]. Inflamm Bowel Dis, 2015, 21(2): 276-286.
30 CHIARO TR, SOTO R, ZAC STEPHENS W, et al. A member of the gut mycobiota modulates host purine metabolism exacerbating colitis in mice[J]. Sci Transl Med, 2017, 9(380): eaaf9044.
31 LIMON J J, TANG J, LI D, et al. Malassezia is associated with Crohn's disease and exacerbates colitis in mouse models[J]. Cell Host Microbe, 2019, 25(3): 377-388.e6.
32 TARRIS G, DE ROUGEMONT A, CHARKAOUI M, et al. Enteric viruses and inflammatory bowel disease[J]. Viruses, 2021, 13(1): 104.
33 GOGOKHIA L, BUHRKE K, BELL R, et al. Expansion of bacteriophages is linked to aggravated intestinal inflammation and colitis[J]. Cell Host Microbe, 2019, 25(2): 285-299.e8.
34 LAM S, ZUO T, HO M, et al. Review article: fungal alterations in inflammatory bowel diseases[J]. Aliment Pharmacol Ther, 2019, 50(11/12): 1159-1171.
35 MILAJERDI A, EBRAHIMI-DARYANI N, DIELEMAN L A, et al. Association of dietary fiber, fruit, and vegetable consumption with risk of inflammatory bowel disease: a systematic review and meta-analysis[J]. Adv Nutr, 2020, 12(3): 735-743.
36 AKRAM W, GARUD N, JOSHI R. Role of inulin as prebiotics on inflammatory bowel disease[J]. Drug Discov Ther, 2019, 13(1): 1-8.
37 DIEDEREN K, LI J V, DONACHIE G E, et al. Exclusive enteral nutrition mediates gut microbial and metabolic changes that are associated with remission in children with Crohn's disease[J]. Sci Rep, 2020, 10(1): 18879.
38 NICHOLSON M R, MITCHELL P D, ALEXANDER E, et al. Efficacy of fecal microbiota transplantation for Clostridium difficile infection in children[J]. Clin Gastroenterol Hepatol, 2020, 18(3): 612-619.e1.
39 BURRELLO C, GARAVAGLIA F, CRIBIù F M, et al. Therapeutic faecal microbiota transplantation controls intestinal inflammation through IL10 secretion by immune cells[J]. Nat Commun, 2018, 9(1): 5184.
40 JAKUBCZYK D, LESZCZY?SKA K, GóRSKA S. The effectiveness of probiotics in the treatment of inflammatory bowel disease (IBD): a critical review[J]. Nutrients, 2020, 12(7): 1973.
Options
文章导航

/

〈 〉